ConSynance Therapeutics, Inc.
Biotechnology ResearchNew York, United States2-10 Employees
ConSynance Therapeutics, Inc. is a late-stage and preclinical biotechnology research company focused on rare central nervous system disorders. Its lead candidate, CSTI-500, is a first-in-class small molecule designed to inhibit triple monoamine reuptake, with Phase I trials in healthy volunteers indicating safety and central nervous system engagement, and current recruitment for a Phase I study in Prader-Willi syndrome to assess pharmacokinetics and safety. The company also is advancing CSTI-200, a GlyT-1 inhibitor in preclinical stages intended for potential use in Parkinson’s disease-related dyskinesia and motor fluctuations, with a mechanism that may offer tolerability advantages. Additionally, ConSynance holds a license in Greater China for HBS-102, a Melanin-Concentrating Hormone 1 receptor antagonist formerly known as CSTI-100, while Harmony Biosciences retains global rights outside Greater China; this asset originated from an agreement reached in 2021. Based in Rensselaer, New York, the company operates with a focus on developing first-in-class therapies for CNS-related rare diseases and related neurological conditions.
1-888-653-2347 
support@leadiq.com 
